ABSTRACT
Biomimetic strategies can be adopted to improve biopharmaceutical aspects. Subsequently, Biomimetic reconstitutable pegylated amphiphilic lipid nanocarriers have high translational potential for systemic controlled drug delivery;however, such an improvised system for systemic aspirin delivery exploring nanotechnology is not available. Systemic administration of aspirin and its controlled delivery can significantly control blood clotting events, leading to stroke, which has immediate applications in cardiovascular diseases and Covid-19. In this work, we are developing aspirin sustained release pegylated amphiphilic self-assembling nanoparticles to develop reconstitutable aspirin injections by solvent-based co-precipitation method with phase inversion technique that leads to novel "biomimetic niosomal nanoparticles (BNNs).” DOE led optimization is done to develop Design of space for optimized particles. Upon reconstitution of solid powder, the particle size was 144.8 ± 12.90 nm with a surface charge of -29.2 ± 2.24 mV. The entrapment efficiency was found to be 49 ± 0.15%, wherein 96.99 ± 1.57% of the drug was released in 24hr showing super case II transport-based drug release mechanism. The formulation has the least hemolysis while showing significant suppression of platelet aggregation. MTT assay does not show any significant cytotoxicity. This is a potential nanoparticle that can be explored for developing aspirin injection, which is not available.
ABSTRACT
Precision medicines are next-generation medicines that apply logistics to improve the efficacy of therapy, reduce safety issues, and reduce patient non-compliance. In this line, we propose a new concept of combining diagnostics with prophylaxis and token the idea of “prophynostics.” Detection followed by prophylactic therapy can prevent disease occurrence. That is particularly important in the case of situations like preventing COVID-19 viral spreading and seizure prevention in epilepsy. However, efforts to achieve this goal is somewhat elusive. This work reports a device platform for detection, followed by the delivery of nicotine through two different routes. Modeling of the detection of a suitable clinical situation is done by choosing epileptic seizure detection. Subsequently, we designed and developed a vibration dependent detection device for detecting seizure type vibrations. For attaining rapid loading dose in patients, delivery through the sublingual route is planned. For that, appropriate nicotine, aspirin, paracetamol sublingual patch is designed and developed. To achieve prolonged delivery of a sustained dose of nicotine in patients, transdermal delivery is planned. For that, suitable nicotine, aspirin, and paracetamol transdermal patch are designed and developed. The platform possibilities of the delivery systems are demonstrated using drugs from various BCS classification system. The drug release properties of the optimized patches are fitted with different models such as zero order, first order, Higuchi, and Koresmayer-Peppas and optimized the release profile as per requirements. This combined system can overcome issues like addiction possibilities of nicotine while exploring it for prophylaxis. Nicotine proposed to have anti-COVID and antiepileptic properties in addition to the anti-inflammatory properties of NSAID's;for such purpose, this type of device can be developed and used. © (2021) Society for Biomaterials & Artificial Organs #20041820
ABSTRACT
COVID-19 pandemic is now beyond control and needs easily translatable therapeutic medicines. Here, the possibilities of developing “prophylactic antiviral medicines”as new medicines that can be interfaced with medical devices are discussed exploring novel molecular pathways, biomimetic engineering approaches and nanomedicines. © (2020) Society for Biomaterials & Artificial Organs #20039820